Lv12
60 积分 2020-10-14 加入
Cemiplimab as Second-Line Therapy for Patients with Recurrent Cervical Cancer: A United States-based Cost-effectiveness Analysis
2小时前
待确认
Postmarketing Reports of Incomplete Dosing-Related Complications with Self-Injected PCSK9 Inhibitors: A Descriptive Study and Disproportionality Analysis
4天前
已完结
Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study
6天前
已完结
Statin intolerance: new data and further options for treatment
19天前
已完结
皖公网安备34019202002308
